SEARCH

SEARCH BY CITATION

References

  • Aliberti JC, Machado FS, Souto JT, Campanelli AP, Teixeira MM, Gazzinelli RT et al. (1999). beta-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun 67 (9): 48194826.
  • Aliberti JC, Souto JT, Marino AP, Lannes-Vieira J, Teixeira MM, Farber J et al. (2001). Modulation of chemokine production and inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection. Am J Pathol 158 (4): 14331440.
  • Altclas J, Sinagra A, Dictar M, Luna C, Veron MT, De Rissio AM et al. (2005). Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 36 (2): 123129.
  • Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA (1991). Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz 86 (2): 187200.
  • Bogdan C (2001). Nitric oxide and the immune response. Nat Immunol 2 (10): 907916.
  • Bogdan C, Rollinghoff M, Diefenbach A (2000a). Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 12 (1): 6476.
  • Bogdan C, Rollinghoff M, Diefenbach A (2000b). The role of nitric oxide in innate immunity. Immunol Rev 173: 1726.
  • Bonaventura D, de SOF, Togniolo V, Tedesco AC, da Silva RS, Bendhack LM (2004). A macrocyclic nitrosyl ruthenium complex is a NO donor that induces rat aorta relaxation. Nitric Oxide 10 (2): 8391.
  • Brener Z (1962a). [Observations on immunity to superinfections in mice experimentally inoculated with Trypanosoma cruzi and subjected to treatment.]. Rev Inst Med Trop Sao Paulo 4: 119123.
  • Brener Z (1962b). Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 4: 389396.
  • Caldas IS, Talvani A, Caldas S, Carneiro CM, de Lana M, da Matta Guedes PM et al. (2008). Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res 103 (2): 413421.
  • Cancado JR (2002). Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44 (1): 2937.
  • Celada A, Gray PW, Rinderknecht E, Schreiber RD (1984). Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med 160 (1): 5574.
  • Coura JR, de Abreu LL, Willcox HP, Petana W (1997). [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Rev Soc Bras Med Trop 30 (2): 139144.
  • Docampo R (1990). Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 73 (1): 127.
  • Fabbro De Suasnabar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M et al. (2000). Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 42 (2): 99109.
  • Filardi LS, Brener Z (1987). Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 81 (5): 755759.
  • Freire-de-Lima CG, Nascimento DO, Soares MB, Bozza PT, Castro-Faria-Neto HC, de Mello FG et al. (2000). Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403 (6766): 199203.
  • Galvao LM, Nunes RM, Cancado JR, Brener Z, Krettli AU (1993). Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg 87 (2): 220223.
  • Green LC, Tannenbaum SR, Goldman P (1981). Nitrate synthesis in the germfree and conventional rat. Science 212 (4490): 5658.
  • Guedes PM, Veloso VM, Caliari MV, Carneiro CM, Souza SM, de Lana M et al. (2007). Trypanosoma cruzi high infectivity in vitro is related to cardiac lesions during long-term infection in Beagle dogs. Mem Inst Oswaldo Cruz 102 (2): 141147.
  • Guedes PMM, Fietto JLR, Lana M, Bahia MT (2006). Advances in Chagas disease chemotherapy anti-infective agents in medicinal. Chemistry 5 (2): 11.
  • Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL et al. (2000). Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 63 (3–4): 111118.
  • Machado FS, Martins GA, Aliberti JC, Mestriner FL, Cunha FQ, Silva JS (2000). Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation 102 (24): 30033008.
  • Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S et al. (2008). Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156 (1): 3743.
  • Martins GA, Petkova SB, Machado FS, Kitsis RN, Weiss LM, Wittner M et al. (2001). Fas-FasL interaction modulates nitric oxide production in Trypanosoma cruzi-infected mice. Immunology 103 (1): 122129.
  • Michailowsky V, Murta SM, Carvalho-Oliveira L, Pereira ME, Ferreira LR, Brener Z et al. (1998). Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob Agents Chemother 42 (10): 25492556.
  • Molina J, Martins-Filho O, Brener Z, Romanha AJ, Loebenberg D, Urbina JA (2000). Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 44 (1): 150155.
  • Nathan C, Shiloh MU (2000). Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA 97 (16): 88418848.
  • Rassi A, Amato Neto V, de Siqueira AF, Ferriolli Filho F, Amato VS, Rassi Junior A (1999). [Protective effect of benznidazole against parasite reactivation in patients chronically infected with Trypanosoma cruzi and treated with corticoids for associated diseases]. Rev Soc Bras Med Trop 32 (5): 475482.
  • Rodrigues GJ, Lunardi CN, Lima RG, Santos CX, Laurindo FR, da Silva RS et al. (2008). Vitamin C improves the effect of a new nitric oxide donor on the vascular smooth muscle from renal hypertensive rats. Nitric Oxide 18 (3): 176183.
  • Russomando G, de Tomassone MM, de Guillen I, Acosta N, Vera N, Almiron M et al. (1998). Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction. Am J Trop Med Hyg 59 (3): 487491.
  • Schmunis GA (2007). Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102 (Suppl. 1): 7585.
  • Segura MJ, Genovese OM, Segura E, Sanz OP, Sica RE (1994). Central motor conduction in human chronic Chagas' disease. Arq Neuropsiquiatr 52 (1): 2931.
  • Silva JJ, Osakabe AL, Pavanelli WR, Silva JS, Franco DW (2007). In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors. Br J Pharmacol 152 (1): 112121.
  • Silva JS, Vespa GN, Cardoso MA, Aliberti JC, Cunha FQ (1995). Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun 63 (12): 48624867.
  • Silva LHP, Nussenzweig V (1953). Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco. Folia Clin Biol 20: 191203.
  • Sosa Estani S, Segura EL (1999). Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Mem Inst Oswaldo Cruz 94 (Suppl. 1): 363365.
  • Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C (1998). Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 59 (4): 526529.
  • Urbina JA (1999). Parasitological cure of Chagas disease: is it possible? Is it relevant?. Mem Inst Oswaldo Cruz 94 (Suppl. 1): 349355.
  • Viotti R, Vigliano C, Armenti H, Segura E (1994). Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127 (1): 151162.
  • Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG et al. (2006). Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144 (10): 724734.
  • WHO (2005). Seventeenth Programme Report of the UNICEF/UNDP/World (Progress 2003–2004). World Health Organization: Geneva, pp. 3133. Special programme for research and training in tropical disease.